Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
77 hedge funds and large institutions have $162M invested in Mersana Therapeutics in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 13 reducing their positions, and 6 closing their positions.
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
154% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 13
18% more funds holding
Funds holding: 65 → 77 (+12)
0.25% more ownership
Funds ownership: 3.1% → 3.35% (+0.25%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less capital invested
Capital invested by funds: $194M → $162M (-$32.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$9.82M |
| 2 |
BlackRock
New York
|
+$7.03M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.63M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$786K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.28M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.1M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.54M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$1.04M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$603K |
MRSN Hedge Fund Activity: Q2 2019 in Review
77 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q2 2019, worth a combined $162M — down 17% from $194M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MRSN positions and 6 closed out — a net gain of 14 holders — while 33 added to existing stakes and 13 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $9.82M. The largest seller was EcoR1 Capital, cutting an estimated $4.28M.
- 77 institutional investors held Mersana Therapeutics (MRSN) as of Q2 2019, up from 65 in Q1 2019.
- Funds reported $162M of Mersana Therapeutics stock for Q2 2019, down 17% quarter-over-quarter.
- 20 funds opened new Mersana Therapeutics positions in Q2 2019 and 6 closed out, a net change of +14 holders.
- The largest Mersana Therapeutics buyer in Q2 2019 was Boxer Capital, an estimated $9.82M added.
- The largest Mersana Therapeutics seller in Q2 2019 was EcoR1 Capital, an estimated $4.28M sold.
Based on aggregated 13F filings for Q2 2019.